✦ LIBER ✦

Erratum to: A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia

✍ Scribed by Ogawa, Yoshiaki; Ogura, Michinori; Suzuki, Tatsuya; Ando, Kiyoshi; Uchida, Toshiki; Shirasugi, Yukari; Tobinai, Kensei; Lee, Je Hwan; Kase, Masazumi; Katsura, Koichi; Hotta, Tomomitsu

Book ID: 121533720
Publisher: Carden Jennings Publishing
Year: 2013
Tongue: English
Weight: 161 KB
Volume: 99
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-013-1491-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I/II study of ofatumumab (GSK184

A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia

✍ Yoshiaki Ogawa, Michinori Ogura, Tatsuya Suzuki… 📂 Article 📅 2013 🏛 Carden Jennings Publishing 🌐 English ⚖ 275 KB

Bendamustine Combined With Rituximab in

Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group

✍ Fischer, K.; Cramer, P.; Busch, R.; Stilgenbauer, S.; Bahlo, J.; Schweighofer, C 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 141 KB

Phase II Study of Lenalidomide and Ritux

Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

✍ Badoux, X. C.; Keating, M. J.; Wen, S.; Wierda, W. G.; O'Brien, S. M.; Faderl, S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 137 KB

Japanese phase II study of 90Y-ibritumom

Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma

✍ Kensei Tobinai; Takashi Watanabe; Michinori Ogura; Yasuo Morishima; Tomomitsu Ho 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB

Substantial Susceptibility of Chronic Ly

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

✍ Roberts, A. W.; Seymour, J. F.; Brown, J. R.; Wierda, W. G.; Kipps, T. J.; Khaw, 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 550 KB

Phase I study of obinutuzumab (GA101) in

Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma

✍ Ogura, Michinori; Tobinai, Kensei; Hatake, Kiyohiko; Uchida, Toshiki; Suzuki, Ta 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB